Search - tctmd.com

Displaying 81 - 100 of 193

Sort: Relevancy | Date

News Conference News ACC 2014

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Jason Kahn

March 31, 2014

News Industry News

Boston Scientific Receives CE Mark Approval for REBEL™ Platinum Chromium Coronary Stent System

March 12, 2014

News Daily News

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

February 12, 2014

News Daily News

DUTCH PEERS Publicado: Los Stents liberadores de Zotarolimus y Everolimus de 3ª Generación son Equivalentes

February 12, 2014

News Industry News

Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement for Promus PREMIER™ Stent System

December 05, 2013

News Industry News

Boston Scientific Receives FDA Approval For Promus Premier™ Everolimus-Eluting Platinum Chromium Coronary Stent System

November 24, 2013

News Conference News TCT 2013

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

October 31, 2013

Presentation TCT 2013

TCT-15. Results of the Primary Endpoint of the PLATINUM PLUS Trial: A Prospective, Randomized, Multi-center Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS...

Presenter: Jean Fajadet

October 29, 2013

Presentation TCT 2013

The Promus Element Everolimus-Eluting Stent: Design Considerations and Clinical Trial Results (from PLATINUM to HOST-ASSURE)

Presenter: Hyo-Soo Kim

October 28, 2013

News Industry News

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

October 28, 2013

News Industry News

Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013

October 17, 2013

News Daily News

在使用DES接受PCI治疗的患者中，西洛他唑与双倍剂量氯吡格雷一样安全

Yael L. Maxwell

September 20, 2013

News Daily News

El Cilostazol es Seguro como la Dosis Doble de Clopidogrel en Pacientes sometidos a PCI con un SLF

Yael L. Maxwell

September 20, 2013

News Daily News

Cilostazol as Safe as Double-Dose Clopidogrel in Patients Undergoing PCI with DES

Yael L. Maxwell

September 20, 2013

News Industry News

Boston Scientific Concludes Enrollment In Randomized, Multicenter, Pivotal Study Of SYNERGY™ Coronary Stent System

September 12, 2013

News Conference News ESC 2013

Meta-analysis: Best Outcomes Seen with Newer-Generation DES in Women

Yael L. Maxwell

September 02, 2013

News Daily News

对氯吡格雷产生高血小板反应性的DES患者未出现死亡风险增高

L.A. McKeown

August 12, 2013

News Daily News

No Increased Mortality Risk for DES Patients with High Platelet Reactivity on Clopidogrel

L.A. McKeown

August 12, 2013

News Daily News

No hay un Mayor Riesgo de Mortalidad para Pacientes SLF con Reactividad Alta al Clopidogrel

L.A. McKeown

August 12, 2013

Presentation EuroPCR 2013

One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study

Presenter: 13956|Raul Moreno

May 31, 2013

Advertisement

NEXT at 2 Years: Nobori DES Still Noninferior to Xience/Promus

Boston Scientific Receives CE Mark Approval for REBEL™ Platinum Chromium Coronary Stent System

DUTCH PEERS Published: Third-Generation Zotarolimus, Everolimus Stents Equivalent

DUTCH PEERS Publicado: Los Stents liberadores de Zotarolimus y Everolimus de 3ª Generación son Equivalentes

Boston Scientific and The Medicines Company Announce U.S. Co-Promotion Agreement for Promus PREMIER™ Stent System

Boston Scientific Receives FDA Approval For Promus Premier™ Everolimus-Eluting Platinum Chromium Coronary Stent System

DUTCH PEERS: Third-Generation Stents Equivalent, Effective

TCT-15. Results of the Primary Endpoint of the PLATINUM PLUS Trial: A Prospective, Randomized, Multi-center Trial to Assess the Everolimus-Eluting Coronary Stent System (PROMUS...

The Promus Element Everolimus-Eluting Stent: Design Considerations and Clinical Trial Results (from PLATINUM to HOST-ASSURE)

Boston Scientific Announces Schedule Of Major Presentations At Transcatheter Cardiovascular Therapeutics 2013

Medtronic to Unveil CoreValve U.S. Pivotal Trial Results at TCT 2013

在使用DES接受PCI治疗的患者中，西洛他唑与双倍剂量氯吡格雷一样安全

El Cilostazol es Seguro como la Dosis Doble de Clopidogrel en Pacientes sometidos a PCI con un SLF

Cilostazol as Safe as Double-Dose Clopidogrel in Patients Undergoing PCI with DES

Boston Scientific Concludes Enrollment In Randomized, Multicenter, Pivotal Study Of SYNERGY™ Coronary Stent System

Meta-analysis: Best Outcomes Seen with Newer-Generation DES in Women

对氯吡格雷产生高血小板反应性的DES患者未出现死亡风险增高

No Increased Mortality Risk for DES Patients with High Platelet Reactivity on Clopidogrel

No hay un Mayor Riesgo de Mortalidad para Pacientes SLF con Reactividad Alta al Clopidogrel

One-Year Outcomes in 1010 Unselected Patients Treated with the PROMUS Element Everolimus-Eluting Stent: The Multicenter PROMUS Element European Post-Approval Surveillance Study

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content